Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onvansertib + LDAC or Decitabine in AML
NCT03303339Phase 2Completed
- Sponsor
- Cardiff Oncology
- Start
- Nov 2017
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of onvansertib in acute myeloid leukemia (AML), sponsored by Cardiff Oncology. Started Nov 2017; status: completed.
02
Drugs
onvansertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03303339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303339.